'In a study published (on Thursday, 22nd December 2016) , an experimental (rVSV-vectored) vaccine against the Ebola virus has been found to be 100% effective! This study and its results have emerged as a great sigh of relief not only for Africa (this disease created havoc in 2014 by causing death of over 11,000 people!) but also......'
If you find it interesting and worth sharing, please do spread the news in your social network.
In a study published in 'The Lancet' (on Thursday, 22nd December 2016) , an experimental (rVSV-vectored) vaccine against the Ebola virus has been found to be 100% effective!
<div style="display: table-cell"><div><img src="https://upload.wikimedia.org/wikipedia/commons/thumb/7/78/Study_Participant_Receives_NIAID-GSK_Candidate_Ebola_Vaccine.jpg/320px-Study_Participant_Receives_NIAID-GSK_Candidate_Ebola_Vaccine.jpg" alt="no longer available" style="float: left;padding-right:12px"></div>
This study and its results have emerged as a great sigh of relief not only for Africa (this disease created havoc in 2014 by causing death of over 11,000 people!), but also for the entire world where the Ebola Virus has been spreading ceaselessly. As quoted by Dr. KeÏta Sakoba, director of Guinea's 'National Agency for Health Security'.
Quote:Ebola left a devastating legacy in our country. We are proud that we have been able to contribute to developing a vaccine that will prevent other nations from enduring what we endured”</div>
About this 'Ebola Vaccine'
rVSV-ZEBOV, the vaccine used in the study, is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus.
In this study, the effect of rVSV-ZEBOV in preventing Ebola virus disease in contacts and contacts of contacts of recently confirmed cases in Guinea, west Africa was tested.
Following is the brief of their story:
In 2015, this experimental vaccine was administered to residents of Guinea 'who were in contact with patients who had recently confirmed cases of Ebola'.
Few months post these early trials, the WHO identified the preliminary results of the trials as an “extremely promising development.”
The trial involving > 11000 people, was later led by WHO in conjunction with Guinea’s Ministry of Health.
Total 5,837 people were administered the rVSV-ZEBOV vaccine, and none recorded any case of Ebola post 10 days or longer.
Vaccine side effects in some subjects were observed, but were limited to headaches, fatigue and muscle pain. Two subjects had serious reactions, one who having an allergic reaction.
Ring strategy of this study for 100% Effective Ebola Vaccine
Ebola is not new to the world (first discovered in 1976). Being limited to isolated African communities for almost 3 decades, its outbreaks were always manageable, and hence wasn't considered a major threat.
But, in 2014, a major outbreak took place, wherein Ebola virus reached cities and started spreading like wildfire (catching the entire global health community off guard and clueless about this sudden and huge outbreak). From Africa, it started spreading to other continents/countries/states/cities and countrysides. This called for a concerted effort.
Categorized as a highly contagious virus, Ebola can spread once patients are symptomatic. So, the relatives of the patients are at great risk of exposure while they try to take care of their loved ones. With an aim to combat this, researchers designed the vaccine administration approach in such a way that the Ebola Vaccine should be doled out to "clusters” or “rings” — groups of people who had been in contact with an Ebola patient (same strategy that was used to eradicate smallpox).
The logic behind this approach, as explained by John-Arne Rottingen of the Norwegian Institute of Public Health to CNN is quite legit:
Quote:“The premise is that by vaccinating all people who have come into contact with an infected person, you create a protective ‘ring’ and stop the virus from spreading further”After this huge reported success, the Ebola vaccine production has been fast tracked by US and European regulatory agencies.
Merck, Sharp & Dohme manufactured the vaccine for the trial and are producing for further actions as well.
As per the promise of Merck: 300,000 doses of the vaccine will be available in case of a new Ebola flareup. Merck will be submitting the Ebola vaccine for licensing by the close of 2017.
Following is the entire research paper published in "The Lancet":
EbolaVaccine100%Protecion.pdf (Size: 857.3 KB / Downloads: 5)
<input type="submit" value="Ebola Virus Details" class="btn btn-info" style="height:30px;background:#005EA7;color:white;cursor:pointer;font-weight:bold;border:none">
MS(Research) Scholar, IIT Delhi (Alumnus)
Advisor for the Biotech Students portal (BiotechStudents.com)
Computational Researcher in BioSciences at a leading MNC
Top Biotech Companies | Top places to work
Indian Biotech Companies and Job Openings
Aiming a PhD in Top Grad School? | These are the Important Points to Consider
Careers in Biotechnology | A list of various Options
Biotechnology Competitive Exams in India